A Phase I/II Study Of OSI-774 [erlotinib] In Combination With Cisplatin In Patients With Recurrent Or Metastatic Squamous Cell Cancer Of The Head And Neck

Trial Profile

A Phase I/II Study Of OSI-774 [erlotinib] In Combination With Cisplatin In Patients With Recurrent Or Metastatic Squamous Cell Cancer Of The Head And Neck

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2012 Actual patient number is 51 as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top